Biotech Stock Still Up 700% Despite 30% Drop This Year as One Fund Discloses $9 Million Exit | The Motley Fool

This Boston-based biotech develops therapies for neurological disorders, with a pipeline targeting depression, tremor, and rare epilepsies.